Hepatitis B is a major public health problem even though safe and effective vaccines have been available for over 10 years.
Because hepatitis B infection is largely asymptomatic with long term complications occurring after many years it has not received the attention it deserves Strategies to immunise those at high risk have failed to control the disease.
Delegates to the World Health Assembly of the World Health Organisation recommended in May 1992 that all countries should integrate hepatitis B vaccination into their national immunisation programmes by 1997.
Some western European countries remain unconvinced that the burden of disease warrants the expense of universal vaccination.
However, epidemiological data and economic evaluation show that universal hepatitis B vaccination is cost effective in countries with low endemicity and that it will control hepatitis B, reinforcing the necessity for action.
Mots-clés Pascal : Vaccination, Virus hépatite B, Hepadnaviridae, Virus, Homme, Législation, Programme, Stratégie, Analyse avantage coût, Sécurité, Facteur risque
Mots-clés Pascal anglais : Vaccination, Hepatitis B virus, Hepadnaviridae, Virus, Human, Legislation, Program, Strategy, Cost benefit analysis, Safety, Risk factor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0241264
Code Inist : 002B02W. Création : 11/06/1997.